Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

Yee Peng Phoon, Jared E. Lopes, Lukas W. Pfannenstiel, C. Marcela Diaz-Montero, Ye F. Tian, Marc S. Ernstoff, Pauline Funchain, XiaoXia Li, Heather C. Losey, Raymond J. Winquist, Brian R. Gastman

Cancer Res (2023) 83 (7_Supplement): 1818.

https://doi.org/10.1158/1538-7445.AM2023-1818

Published: 04 April 2023

View article titled, Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

Journal Articles

Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma

Benjamin Switzer, Manu R. Pandey, Alexandra Valentine, Agnieszka Witkiewicz, Erik Knudsen, Kristopher Attwood, Joseph Tario, Pauline Funchain, Joseph J. Drabick, Hemn Mohammadpour, Marc S. Ernstoff, Igor Puzanov, Elizabeth A. Repasky, Shipra Gandhi

Cancer Res (2022) 82 (12_Supplement): CT568.

https://doi.org/10.1158/1538-7445.AM2022-CT568

Published: 15 June 2022

View article titled, Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma

Journal Articles

Abstract 1983: Cancer exosomes immunosuppressive activity in the absence of contaminating soluble factors is multifactorial

Shin La Shu, Junko Matsuzaki, Cheryl Allen, Yunchen Yang, Edward Hurley, Kunle Odunsi, Yun Wu, Marc S. Ernstoff

Cancer Res (2019) 79 (13_Supplement): 1983.

https://doi.org/10.1158/1538-7445.AM2019-1983

Published: 01 July 2019

View article titled, Abstract 1983: Cancer exosomes immunosuppressive activity in the absence of contaminating soluble factors is multifactorial

Journal Articles

Abstract 4057: Measurement of myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), CD8⁺ and CD4⁺T-cells, and cytokines/chemokines in patients with metastatic melanoma treated with pembrolizumab and propranolol

Shipra Gandhi, Manu Pandey, Kristopher M. Attwood, Cheryl Allen, Joseph Tario, Shin La Shu, Maria Levis, Suzanne M. Stack, Paul Wallace, Paul Bogner, Igor Puzanov, Mark J. Bucsek, Elizabeth Repasky, Marc S. Ernstoff

Cancer Res (2019) 79 (13_Supplement): 4057.

https://doi.org/10.1158/1538-7445.AM2019-4057

Published: 01 July 2019

View article titled, Abstract 4057: Measurement of myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), CD8+ and CD4+T-cells, and cytokines/chemokines in patients with metastatic melanoma treated with pembrolizumab and propranolol

Journal Articles

Abstract 5087: Human melanoma exosomes induce metabolic reprogramming in human adult dermal fibroblasts

Shin La Shu, Cheryl L. Allen, Yunchen Yang, Orla Maguire, Hans Minderman, Arindam Sen, Michael J. Ciesielski, Katherine A. Collins, Peter J. Bush, Martin Morgan, Yun Wu, Richard B. Bankert, Marc S. Ernstoff

Cancer Res (2018) 78 (13_Supplement): 5087.

https://doi.org/10.1158/1538-7445.AM2018-5087

Published: 01 July 2018

View article titled, Abstract 5087: Human melanoma exosomes induce metabolic reprogramming in human adult dermal fibroblasts

Journal Articles

Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma

Ahmad A. Tarhini, Paul H. Frankel, Christopher Ruel, Marc S. Ernstoff, Timothy M. Kuzel, Theodore F. Logan, Nikhil I. Khushalani, Hussein A. Tawbi, Kim A. Margolin, Sanjay Awasthi, David F. McDermott, Alice Chen, Primo N. Lara, John M. Kirkwood

Cancer Res (2017) 77 (13_Supplement): 3827.

https://doi.org/10.1158/1538-7445.AM2017-3827

Published: 01 July 2017

View article titled, Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma

Journal Articles

Abstract 3158: Ex vivo expansion and activation of human lymphocytes with a selective activator of effector cells

Jared E. Lopes, Jan L. Fisher, Heather C. Losey, Marc S. Ernstoff, Juan C. Alvarez

Cancer Res (2015) 75 (15_Supplement): 3158.

https://doi.org/10.1158/1538-7445.AM2015-3158

Published: 01 August 2015

View article titled, Abstract 3158: Ex vivo expansion and activation of human lymphocytes with a selective activator of effector cells

Journal Articles

Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone

Cancer Res (2015) 75 (15_Supplement): 2860.

https://doi.org/10.1158/1538-7445.AM2015-2860

Published: 01 August 2015

View article titled, Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone

Journal Articles

VISTA Is an Immune Checkpoint Molecule for Human T Cells

J. Louise Lines, Eirini Pantazi, Justin Mak, Lorenzo F. Sempere, Li Wang, Samuel O'Connell, Sabrina Ceeraz, Arief A. Suriawinata, Shaofeng Yan, Marc S. Ernstoff, Randolph Noelle

Cancer Res (2014) 74 (7): 1924–1932.

https://doi.org/10.1158/0008-5472.CAN-13-1504

Published: 31 March 2014

View article titled, VISTA Is an Immune Checkpoint Molecule for Human T Cells

Includes: Supplementary data

Journal Articles

Abstract 3413: Dissecting the combination of gemcitabine and the Chk1 inhibitor MK-8776 in vitro and in vivo: cell cycle perturbation and the impact of administration schedule.

Alan Eastman, Ryan Montano, Ruth Thompson, Nadeem Khan, Huagang Hou, Lionel D. Lewis, John D. Seigne, Marc S. Ernstoff

Cancer Res (2013) 73 (8_Supplement): 3413.

https://doi.org/10.1158/1538-7445.AM2013-3413

Published: 15 April 2013

View article titled, Abstract 3413: Dissecting the combination of gemcitabine and the Chk1 inhibitor MK-8776 in vitro and in vivo: cell cycle perturbation and the impact of administration schedule.

Journal Articles

Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

Paulo C. Rodriguez, Marc S. Ernstoff, Claudia Hernandez, Michael Atkins, Jovanny Zabaleta, Rosa Sierra, Augusto C. Ochoa

Cancer Res (2009) 69 (4): 1553–1560.

https://doi.org/10.1158/0008-5472.CAN-08-1921

Published: 12 February 2009

View article titled, Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

Includes: Supplementary data

Journal Articles

Suppressor (CD8+/CD28-) T cells are increased in cancer patients and inhibit helper T-cell proliferation.

Todd S. Crocenzi, Christopher P. Tretter, Mary Waugh, Marc S. Ernstoff

Cancer Res (2004) 64 (7_Supplement): 499–500.

Published: 01 April 2004

View article titled, Suppressor (CD8+/CD28-) T cells are increased in cancer patients and inhibit helper T-cell proliferation.

Journal Articles

Expression of Fas(APO-1/CD95) in Tumor-infiltrating and Peripheral Blood Lymphocytes in Patients with Renal Cell Carcinoma

Gaetano Cardi, John A. Heaney, Alan R. Schned, Marc S. Ernstoff

Cancer Res (1998) 58 (10): 2078–2080.

Published: 01 May 1998

View article titled, Expression of Fas(APO-1/CD95) in Tumor-infiltrating and Peripheral Blood Lymphocytes in Patients with Renal Cell Carcinoma

Journal Articles

T-Cell Receptor ζ-Chain Expression on Tumor-infiltrating Lymphocytes from Renal Cell Carcinoma

Gaetano Cardi, John A. Heaney, Alan R. Schned, Dorothy M. Phillips, Mark T. Branda, Marc S. Ernstoff

Cancer Res (1997) 57 (16): 3517–3519.

Published: 01 August 1997

View article titled, T-Cell Receptor ζ-Chain Expression on Tumor-infiltrating Lymphocytes from Renal Cell Carcinoma

Journal Articles

Immunological Effects of Treatment with Sequential Administration of Recombinant Interferon γ and α in Patients with Metastatic Renal Cell Carcinoma during a Phase I Trial

Marc S. Ernstoff, William Gooding, Suresh Nair, Robert R. Bahnson, Linda M. Miketic, Barbara Banner, Roger Day, Theresa Whiteside, Linda Titus-Ernstoff, John M. Kirkwood

Cancer Res (1992) 52 (4): 851–856.

Published: 01 February 1992

View article titled, Immunological Effects of Treatment with Sequential Administration of Recombinant Interferon γ and α in Patients with Metastatic Renal Cell Carcinoma during a Phase I Trial

Journal Articles

Dysplastic Nevi in Association with Multiple Primary Melanoma

Linda Titus-Ernstoff, Paul H. Duray, Marc S. Ernstoff, Raymond L. Barnhill, Pamela L. Horn, John M. Kirkwood

Cancer Res (1988) 48 (4): 1016–1018.

Published: 01 February 1988

View article titled, Dysplastic Nevi in Association with Multiple Primary Melanoma

Journal Articles

A Randomized Study of Low and High Doses of Leukocyte α-Interferon in Metastatic Renal Cell Carcinoma: The American Cancer Society Collaborative Trial

John M. Kirkwood, Jules E. Harris, Raul Vera, Steven Sandler, David S. Fischer, Janardan Khandekar, Marc S. Ernstoff, Leo Gordon, Richard Lutes, Philip Bonomi, Bernard Lytton, M. Cobleigh, Samuel J. Taylor, IV

Cancer Res (1985) 45 (2): 863–871.

Published: 01 February 1985

View article titled, A Randomized Study of Low and High Doses of Leukocyte α-Interferon in Metastatic Renal Cell Carcinoma: The American Cancer Society Collaborative Trial

Journal Articles

Urinary Excretion of Interferon, Albumin, and β₂-Microglobulin during Interferon Treatment

Bauer E. Sumpio, Marc S. Ernstoff, John M. Kirkwood

Cancer Res (1984) 44 (8): 3599–3603.

Published: 01 August 1984

View article titled, Urinary Excretion of Interferon, Albumin, and β2-Microglobulin during Interferon Treatment

NARROW

Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma

Abstract 1983: Cancer exosomes immunosuppressive activity in the absence of contaminating soluble factors is multifactorial

Abstract 4057: Measurement of myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), CD8⁺ and CD4⁺T-cells, and cytokines/chemokines in patients with metastatic melanoma treated with pembrolizumab and propranolol

Abstract 5087: Human melanoma exosomes induce metabolic reprogramming in human adult dermal fibroblasts

Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma

Abstract 3158: Ex vivo expansion and activation of human lymphocytes with a selective activator of effector cells

Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone

VISTA Is an Immune Checkpoint Molecule for Human T Cells

Abstract 3413: Dissecting the combination of gemcitabine and the Chk1 inhibitor MK-8776 in vitro and in vivo: cell cycle perturbation and the impact of administration schedule.

Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

Suppressor (CD8+/CD28-) T cells are increased in cancer patients and inhibit helper T-cell proliferation.

Expression of Fas(APO-1/CD95) in Tumor-infiltrating and Peripheral Blood Lymphocytes in Patients with Renal Cell Carcinoma

T-Cell Receptor ζ-Chain Expression on Tumor-infiltrating Lymphocytes from Renal Cell Carcinoma

Immunological Effects of Treatment with Sequential Administration of Recombinant Interferon γ and α in Patients with Metastatic Renal Cell Carcinoma during a Phase I Trial

Dysplastic Nevi in Association with Multiple Primary Melanoma

A Randomized Study of Low and High Doses of Leukocyte α-Interferon in Metastatic Renal Cell Carcinoma: The American Cancer Society Collaborative Trial

Urinary Excretion of Interferon, Albumin, and β₂-Microglobulin during Interferon Treatment

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only